A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis

A Phase III, Randomised, Double-blind, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity of SB17 (Proposed Ustekinumab Biosimilar) Compared to Stelara® in Subjects With Moderate to Severe Plaque Psoriasis

This is a randomised, double-blind, multicentre clinical study to evaluate the efficacy, safety, tolerability, PK, and immunogenicity of SB17 compared to Stelara® in subjects with moderate to severe plaque psoriasis.

Study Overview

• Status: Completed
• Conditions: Psoriasis; Moderate to Severe Plaque Psoriasis
• Intervention / Treatment: Drug: SB17 (Proposed Ustekinumab Biosimilar); Drug: Stelara® (Ustekinumab)

Detailed Description

Subjects will be randomised in a 1:1 ratio to receive either SB17 or Stelara® via subcutaneous injection. At Week 28, subjects receiving Stelara® will be randomised again in a 1:1 ratio to either continue on Stelara® or be transitioned to SB17. Investigational products (IPs) (SB17 or Stelara®) will be administered at Week 0, 4, and then every 12 weeks up to Week 40, and the last assessment will be done at Week 52.

• Study Type: Interventional
• Enrollment (Actual): 503
• Phase: Phase 3

Contacts and Locations

Study Locations

• Czechia
  • Brno, Czechia
    • SB Investigative Site
  • Ostrava, Czechia
    • SB Investigative Site
  • Pardubice, Czechia
    • SB Investigative Site
  • Praha 10, Czechia
    • SB Investigative Site
  • Praha 3, Czechia
    • SB Investigative Site
• Estonia
  • Tallinn, Estonia
    • SB Investigative Site
  • Tartu, Estonia
    • SB Investigative Site
• Hungary
  • Zalaegerszeg, Hungary
    • SB Investigative Site
• Korea, Republic of
  • Seongnam, Korea, Republic of
    • SB Investigative Site
  • Suwon, Korea, Republic of
    • SB Investigative Site
• Latvia
  • Riga, Latvia
    • SB Investigative Site
  • Talsi, Latvia
    • SB Investigative Site
• Lithuania
  • Kaunas, Lithuania
    • SB Investigative Site
  • Vilnius, Lithuania
    • SB Investigative Site
• Poland
  • Elbląg, Poland
    • SB Investigative Site
  • Kielce, Poland
    • SB Investigative Site
  • Krakow, Poland
    • SB Investigative Site
  • Lodz, Poland
    • SB Investigative Site
  • Lublin, Poland
    • SB Investigative Site
  • Rzeszow, Poland
    • SB Investigative Site
  • Siedlce, Poland
    • SB Investigative Site
  • Skierniewice, Poland
    • SB Investigative Site
  • Swidnik, Poland
    • SB Investigative Site
  • Warszawa, Poland
    • SB Investigative Site
• Ukraine
  • Dnipro, Ukraine
    • SB Investigative Site
  • Kharkiv, Ukraine
    • SB Investigative Site
  • Kherson, Ukraine
    • SB Investigative Site
  • Kyiv, Ukraine
    • SB Investigative Site
  • Lviv, Ukraine
    • SB Investigative Site
  • Odesa, Ukraine
    • SB Investigative Site
  • Uzhgorod, Ukraine
    • SB Investigative Site
  • Vinnytsia, Ukraine
    • SB Investigative Site
  • Zaporizhzhia, Ukraine
    • SB Investigative Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Aged 18 years or older at Screening.
• Have plaque psoriasis diagnosed at least 6 months, with or without psoriatic arthritis.
• Have plaque psoriasis with the involvement and severity of total affected BSA ≥ 10%, PASI score of ≥ 12 and PGA score of ≥ 3 (moderate).
• Considered to be a candidate for phototherapy or systemic therapy for psoriasis
• Less than 95 kg of body weight.
• Adequate hematological, renal and hepatic function by central lab.
• Non-childbearing potential female, or childbearing potential female subjects or male subjects with their partners who agree to use at least two forms of appropriate contraception method from Screening until 15 weeks after the last dose of IP.

Exclusion Criteria:

• Have nonplaque forms of psoriasis, including erythrodermic, pustular, guttate, or drug-induced psoriasis.
• Have other skin disease than psoriasis that requires topical or systemic corticosteroids.
• Prior biologic use as any TNF inhibitors within the previous 6 months; any IL-12 or IL-23 inhibitor biologics, IL-17 inhibitor, rituximab, or integrin inhibitor biologics at any time; or other biologics within the longer of either 5 half-lives or 3 months prior to randomisation.
• Known allergic reactions or hypersensitivity to ustekinumab or to any ingredients of Stelara® or SB17
• History of exfoliative dermatitis, reversible posterior leukoencephalopathy syndrome, facial palsy, allergic alveolitis, or non-infectious pneumonia.
• Have received phototherapy or conventional systemic therapy for psoriasis within 4 weeks prior to Randomisation.
• Have received topical therapy for psoriasis within 2 weeks prior to Randomisation.
• Women who are pregnant or nursing at Screening, or men and women planning pregnancy during the study period and until 15 weeks after the last dose of IP.
• Have received a live or live attenuated viral vaccine or a live bacterial vaccine within 4 weeks (for BCG, 12 months) prior to Randomisation.
• Have active or latent tuberculosis.
• History of ongoing infection or a positive test of HBV, HCV, or HIV infection
• History of sepsis, chronic or recurrent infection
• History of malignancy within the last 5 years
• History of lymphoproliferative disease or leukemia
• History of myocardial infarction, NYHA III/IV congestive heart failure, or stroke within 12 months
• Have uncontrolled hypertension or diabetes
• History of uncontrolled psychiatric disorders or risk of suicide

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: SB17 (Proposed Ustekinumab Biosimilar)	Drug: SB17 (Proposed Ustekinumab Biosimilar); Subjects randomised into SB17 group will receive SB17 (45 mg) via subcutaneous injection at Week 0, 4, and then every 12 weeks up to Week 40. Starting at Week 28, subjects transited from Stelara® to SB17 will receive SB17 via subcutaneous injection.
Active Comparator: Stelara® (Ustekinumab)	Drug: SB17 (Proposed Ustekinumab Biosimilar); Subjects randomised into SB17 group will receive SB17 (45 mg) via subcutaneous injection at Week 0, 4, and then every 12 weeks up to Week 40. Starting at Week 28, subjects transited from Stelara® to SB17 will receive SB17 via subcutaneous injection.; Drug: Stelara® (Ustekinumab); Subjects randomised into Stelara® group will receive Stelara® (45 mg) via subcutaneous injection at Week 0, 4, and then every 12 weeks up to Week 40.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percent Change From Baseline in PASI at Week 12	Psoriasis area severity index (PASI) measures the activity of psoriasis through erythema, induration and scaling and can range from 0 to 72. The degree of PASI improvement in terms of percent change from baseline at Week 12 is measured.	Baseline and Week 12

Collaborators and Investigators

• Sponsor: Samsung Bioepis Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): July 6, 2021
• Primary Completion (Actual): February 24, 2022
• Study Completion (Actual): November 25, 2022

Study Registration Dates

• First Submitted: July 8, 2021
• First Submitted That Met QC Criteria: July 8, 2021
• First Posted (Actual): July 19, 2021

Study Record Updates

• Last Update Posted (Actual): May 25, 2025
• Last Update Submitted That Met QC Criteria: May 22, 2025
• Last Verified: May 1, 2025

More Information

Terms related to this study

• Keywords: Psoriasis; Plaque Psoriasis
• Additional Relevant MeSH Terms: Skin Diseases, Papulosquamous; Skin Diseases; Psoriasis; Dermatologic Agents; Ustekinumab
• Other Study ID Numbers: SB17-3001

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No